Tier 4 — mechanistic

The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Steadman Philippon Research Institute study team
ClinicalTrials.gov trial registry record 2021

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Steadman Philippon Research Institute.
Competing interests
Not reported in the registry record.

Study snapshot

DesignProspective randomized blinded multi-arm Phase 1/2 trial with BMAC active treatment in all groups.
ModelAdults aged 40-85 years with knee osteoarthritis.
SamplePlanned enrollment: 100 participants.
InterventionAll participants receive bone marrow aspirate concentrate (BMAC). Fisetin is tested at approximately 20 mg/kg across 10 total treatment days, with or without losartan, against corresponding placebo arms.
DurationApproximately 18 weeks from first fisetin exposure through the final post-BMAC course; patient-reported follow-up extends longer.
EndpointsSafety; Knee pain and function; Patient-reported outcomes; Senescence/SASP biomarkers; BMAC-related outcomes

What the study showed, in plain terms

This trial tests whether adding fisetin, losartan, or both changes outcomes after BMAC treatment for knee osteoarthritis. Because every arm receives BMAC and some arms also receive losartan, it is a combination-treatment study rather than a clean test of fisetin alone.

The September 2026 fisetin clinical-translation review lists the trial with unknown recruitment status and no results. Any future outcome will need arm-specific interpretation before attributing an effect to fisetin.

Key findings

  • Planned sample size is 100.
  • Fisetin is used repeatedly around the BMAC intervention and can be given with or without losartan.
  • No posted results were available at 2026 verification.

What this study can and cannot tell us

  • No results available.
  • Multi-intervention design complicates attribution.
  • Registry status is stale/unknown in the 2026 review.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology